Anzeige
Mehr »
Montag, 06.07.2026 - Börsentäglich über 12.000 News
8,8-Mio.-Nanocap direkt neben Europas Lithium-Giganten - jetzt steigt die Spannung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
18:46UK biotechs struggling to access finance as scale-up concerns grow
12:46Novartis to acquire Myricx Bio in up to $1.5bn deal
12:46Roche pens $490m Astex breast cancer license deal
11:46Besins Healthcare boosts drug delivery portfolio with UniD deal
FrWHO intensifies Ebola-curbing efforts through drug trial and diagnostic rollout
FrUS-UK pharma trade deal paints a costly economic picture for NHS
FrSK bioscience to lead Gates Foundation-funded ROTOR project
FrEuropean Commission approves Novartis' Itvisma to treat SMA
DoIpsen bolsters rare disease pipeline in €700m Memo takeover
DoFDA widens Vertex's Casgevy use for paediatric patients
DoInsilico Medicine, Takeda partner on AI-driven drug discovery
DoInocras, AimedBio team up for cancer treatments
MiQuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform
MiSanofi aims for Nexviazyme approval in younger Pompe disease patients
MiAnthropic debuts AI-driven pharma R&D tool, Claude Science
MiMedical journal retracts Tavneos pivotal paper amid wider regulatory clampdown
MiUS FDA rejects approval of Unicycive's kidney disease therapy
MiEli Lilly and Innovent agree Verzenios commercialisation deal in China
DiLilly and Regeneron amongst first incumbents to FDA's fast-track facility scheme
DiTalawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger
DiAnixa Biosciences secures Korean patent for breast cancer vaccine
DiZymeworks agrees to buy Theravance Biopharma for $929m
29.06.EMA backs market rollback of rare disease drug Tavneos over data concerns
29.06.Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
29.06.FDA issues complete response letter to Sobi's NASP for gout